Drug Profile


Alternative Names: FE 999050; JK 201; R 76713; R 83839; R 83842; Rivizor

Latest Information Update: 22 Feb 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Janssen L.P.
  • Developer Ferring Pharmaceuticals
  • Class Antineoplastics; Triazoles
  • Mechanism of Action Aromatase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Breast cancer; Female infertility; Ovarian cancer

Most Recent Events

  • 24 May 2005 Phase-II clinical trials in Female infertility in Denmark (PO)
  • 06 Mar 2003 A study has been added to the Cancer therapeutic trials section
  • 17 Oct 2000 A study has been added to the Cancer therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top